Skip to main content

Construction of Sterile Pharmaceutical Products Manufacturing Plant was completed

Corporate Announcement

GC Holding AG Strengthens Corporate Governance and Announces New CEO
dr-falk-global-banner

Foundation Nakao for Worldwide Oral Health

New Opportunity for Oral Health Research Funding!

MI Paste® ONE Perio

One Step Anti-Gingivitis Toothpaste with RECALDENT® Technology

GC Initial® LiSi Block

Lithium Disilicate Glass Ceramic CAD/CAM Block

G-ænial™ A’CHORD

Universal Light-Cured Radiopaque Composite Restorative

G-CEM ONE™

Universal Self-Adhesive Resin Cement

GC Initial® LiSi Press

High Strength Lithium Disilicate with HDM Technology

EQUIA Forte® HT

Cost-Effective Long Term Restorative Alternative

Construction of Sterile Pharmaceutical Products Manufacturing Plant was completed

GC Corporation (Kiyotaka Nakao, President & CEO, Bunkyo-ku, Tokyo) and the company, Showa Yakuhin Kako Co., Ltd. (Seiji Yoshida, CEO, Chuo-ku Tokyo), started a project to construct a new manufacturing building for dental products in January 2018. The construction of the new manufacturing plant for sterile pharmaceutical products was completed as planned on June 5th. The new manufacturing plant is a three-story building, with the total space of 5,339.23m2, located in Kawasaki-shi, Kanagawa-ken, Japan.



There were many guests in attendance for the completion ceremony, including Dr. Toshihiko Makino (Vice-President of the Japan Dental Association), Dr. Shigeo Sugiyama (Standing Director from the Japan Dental Association), Mr. Shigeo Nakayama (Chairman of the Japan Dental Pharmaceutical Association) and Mr. Hikaru Ouchi (President of AYUMI Pharmaceutical Corporation). The guests also joined the Shinto ritual ceremony, “Tamagushi-hoten”.



After the ritual ceremony, Yoshimasa Suzuki, Director of GC Corporation, gave a presentation that featured a board displaying the new plant facilities.



At the “Naorai”, a feast after the ritual ceremony, President Kiyotaka Nakao expressed his gratitude to everyone involved in the construction project for an on-time completion of the sterile pharmaceutical product manufacturing plant, which required a highly-controlled environment. He also stated that the GC Group would contribute to dental care not only in Japan, but also around the world by delivering safe and reliable products with the best quality and condition from the new plant, which has cutting-edge facilities.



In his congratulatory speech, Dr. Toshihiko Makino mentioned that he hoped the products manufactured in the top-level aseptic area would emphasize the importance of safe and secure dental care, representing one of the goals for the JDA to achieve.



Production will start at the new plant, positioned as a major manufacturing base for dental pharmaceutical products within the GC Corporation, targeting to contribute to dentistry in Japan and also world-wide.



GC has positioned the 21st Century as the “Century of Health” and is dedicated to become the No. 1 dental company of the world by supporting and improving our end user’s lives through dental care. We will continue our collaborative, group-wide efforts to contribute to our end user’s health and smiles around the world. Your continued support would be much appreciated.